Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06672705 · ClinicalTrials.gov registry record · Phase 1
Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders
A Phase 1 study of Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder and EBV-Related Post-Transplant Lymphoproliferative Disorder, sponsored by Timothy Voorhees.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 2
- Study locations
NCT06672705: Recruiting Phase 1 study of Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder and EBV-Related Post-Transplant Lymphoproliferative Disorder, sponsored by Timothy Voorhees.
NCT06672705 is a Phase 1 study of Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder and EBV-Related Post-Transplant Lymphoproliferative Disorder that is actively recruiting participants, run by Timothy Voorhees. The registered enrollment target is 26 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06672705, a Phase 1 study of Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder and EBV-Related Post-Transplant Lymphoproliferative Disorder, is actively recruiting participants, sponsored by Timothy Voorhees.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase Ib trial tests the safety and effectiveness of epcoritamab in treating patients with post-transplant lymphoproliferative disorder (PTLD) that has come back after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Epcoritamab, a bispecific antibody, binds to a protein called CD3, which is found on T cells (a type of white blood cell). It also binds to a protein called CD20, which is found on B cells (another type of white blood cell) and some lymphoma cells. This may help the immune system kill cancer cells. Giving epcoritamab may be safe and effective in treating patients with relapsed or refractory B-cell PTLD.
Primary Outcome
Will be assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 and American Society for Transplantation and Cellular Therapy (ASTCT) grading for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). The dose limiting toxicity period will be the first 28 days after the first dose of epcoritamab.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Biopsy
- PROCEDURE Positron Emission Tomography
- BIOLOGICAL Epcoritamab
Study Locations (2)
Missouri
- Washington University - St Louis
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2025-06-16 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
What NCT06672705 shows while recruiting
NCT06672705 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% lower).
The record links to 6 conditions, with Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06672705 reports a single indexed study location in Missouri, Ohio.
Frequently Asked Questions
What is clinical trial NCT06672705 about?
NCT06672705 is a clinical study titled "Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders". This phase Ib trial tests the safety and effectiveness of epcoritamab in treating patients with post-transplant lymphoproliferative disorder (PTLD) that has come back after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Epcoritamab, a bispecific antibody,...
What is the current status of trial NCT06672705?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2025-06-16. Estimated completion is 2026-12-31.
What conditions does trial NCT06672705 study?
This clinical trial studies the following conditions: Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder, EBV-Related Post-Transplant Lymphoproliferative Disorder, Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder, Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder, Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder.
What interventions are being tested in trial NCT06672705?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Biopsy (PROCEDURE), Positron Emission Tomography (PROCEDURE), Epcoritamab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06672705?
This trial is sponsored by Timothy Voorhees, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06672705 being conducted?
This trial has 2 study locations across Missouri, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06672705's enrollment target sits among peer trials
26 1483rd of 2000 higher than 506 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI